Lastly, in a preclinical setting, the RAS inhibitor RMC-7977 repressed the phosphorylation of downstream effectors of the MAPK pathway (MEK, ERK, and RSK) and was potent against FLT3-ITD- and RAS-mutated AML cell lines [133]. This evidence concerns the gene FLT3 and acute myeloid leukemia.